Domain Therapeutics rebrands as Kainova Therapeutics to advance GPCR-focused clinical pipeline
The rebrand reflects the company's clinical momentum and ambition to drive the next phase of growth in immuno-oncology and inflammation, as it advances a pipeline of GPCR-modulating therapies